Astrotech
Commercializes mass-spectrometry technology through application-specific security and analytical devices.
Something off on this page? Send us feedback.
Profile
Commercializes AMS mass-spectrometry technology through subsidiaries that develop security, analytical, and process-control devices. 1st Detect, its security subsidiary, holds an exclusive AMS license for passenger, cargo, and narcotics-detection applications.
Astrotech Technologies holds and licenses its AMS platform to application-specific subsidiaries. The group’s devices include TRACER 1000 security detectors, the AgLAB-1000 series for hemp and cannabis processing, BreathTest-1000, and Pro-Control 1000.
1st Detect holds an exclusive AMS license for passenger screening, cargo security, and narcotics detection. Its detectors target airports, borders, cargo hubs, critical infrastructure, corrections, military bases, and law enforcement.
The operating model centers on commercializing AMS through these businesses. The board has authorized a potential sale process for 1st Detect; the reviewed filings do not establish that a sale closed.
Company facts
Categories
Key statistics
Year to date +94.8% · Average volume (30d) 231.0K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| May 13, 2026Q3 FY26 | — | −$2.25 | — | — | $343.0K | — | −2.97% |
| Feb 13, 2026Q2 FY26 | — | −$2.34 | — | — | $148.0K | — | +0.36% |
| Nov 13, 2025Q1 FY26 | — | −$2.07 | — | — | $297.0K | — | 0.00% |
| Sep 25, 2025Q4 FY25 | — | −$1.75 | — | — | $220.0K | — | +2.04% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $261.0K | $534.0K | $220.0K | $297.0K | $148.0K | $343.0K | |
| Gross profit | −$119.0K | −$46.0K | −$257.0K | −$114.0K | −$285.0K | −$232.0K | |
| Operating income | −$4.3M | −$3.9M | −$2.9M | −$3.5M | −$3.9M | −$3.5M | |
| Net income | −$4.0M | −$3.6M | −$2.9M | −$3.5M | −$3.9M | −$3.8M | |
| Diluted EPS | −$2.45 | −$2.18 | −$1.76 | −$2.07 | −$2.34 | −$2.25 | |
| Gross margin | -45.6% | -8.6% | -116.8% | -38.4% | -192.6% | -67.6% | |
| Operating margin | -1,655.6% | -724.2% | -1,326.4% | -1,190.6% | -2,635.8% | -1,006.7% |
Fiscal years (4-quarter sums)FY21 $334.0K · FY22 $869.0K · FY23 $750.0K · FY24 $1.7M · FY25 $1.0M
Revenue by product · Q3 FY26
Revenue by geography · Q3 FY26
Balance sheet, Mar 31, 2026Cash & short-term investments $6.6M · Total debt $2.4M · Total assets $16.2M · Shareholders' equity $12.2M
Dividends
No dividends on record.
Ownership
Shares outstanding 2.01M · Float 1.38M · 68.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Thomas Boone III Pickens · director, officer: CEO | 181.4K | 9.03% | Form 4 | May 16, 2025 |
| Tom Wilkinson · director | 30.9K | 1.54% | Form 4 | Jul 21, 2026 |
| J. Safra Sarasin Holding AG | 27.3K | 1.36% | 13F | May 4, 2026 |
| Thomas Wiley Wilkinson · director | 23.9K | 1.19% | Form 4 | May 16, 2025 |
| Charles Arch Winn · director | 22.0K | 1.09% | Form 4 | Jul 21, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Oct 3, 2025 | Braden Michael Leonard | 10 percent owner | −229,576 | $7.08 |
Peers
- OSI Systems
Rapiscan ETDs overlap in explosives and narcotics screening
- Bruker
ETD and CBRNE instruments overlap in aviation and defense screening
- Teledyne Technologies
FLIR ETDs overlap in portable explosive screening
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Astrotech | $7.15 | +0.58% | $14.4M | — | — | 14.3 | −35.8% |
| OSI Systems | $206.64 | −0.01% | $3.41B | 23.1 | 18.4 | 1.9 | −4.1% |
| Bruker | $57.08 | +0.04% | $8.69B | — | 25.2 | 2.5 | +5.2% |
| Teledyne Technologies | $621.96 | +0.02% | $28.83B | 30.0 | 24.4 | 4.5 | +9.8% |
| Median | 26.6 | 24.4 | 2.5 | +5.2% |